Overview
HBM HOLDINGS-B (2142)
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology...
- Open
- 10.610
- High
- 10.610
- Low
- 10.060
- Prev. Close
- 10.540
- Volume
- 5.10M
- Turnover
- 52.27M
- Avg Price
- 10.243
- Bid/Ask Ratio
- -50.00%
- Amplitude
- 5.22%
- 52wk High
- 17.070
- Volume Ratio
- 1.46
- Turnover Ratio
- 0.59%
- 52wk Low
- 9.280
- HK Mkt Cap
- 8.90B
- Market CapHKD
- 8.90B
- P/ETTM
- 13.43
- P/EDynamic
- 8.75
- P/EStatic
- --
- EPSTTM
- 0.762
- EPSDynamic
- 1.17
- EPSStatic
- --
- BVPS
- 3.77
- P/B
- 2.72
- HK Shares
- 869.27M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 869.27M
- Min lot size
- 1,000
- Currency
- HKD
HBM HOLDINGS-B Analyst Rating
View moreForecast & Rating
Oct 23, 2026- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 2
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 9
Harbour BioMed (2142.HK) opened at HK$10.38, spiked to HK$11.01 in the morning session, then faded through the afternoon to close at HK$10.74, up 3.47% on HK$70.3 million turnover, after the NMPA approved the subcutaneous formulation of batoclimab for generalised myasthenia gravis; buybacks of about 900,000 shares for roughly HK$8.62 million across 2-4 November added support. Q2 revenue rose 20.79% year on year to HK$480.3 million at a 52.97% net margin, yet net profit fell 9.62% to HK$254.4 million, leaving PE at 14.09x. The stock stays below its MA60 of HK$12.91, down 11.09% year to date and 37.08% beneath the 25 August high of HK$17.07, while the consensus target price was raised 20% to HK$24.48. Whether a single-indication ramp can offset the profit decline still awaits the next set of results.
- Nov, 5
Three straight sessions of buybacks and continued digestion of batoclimab's approval lifted HBM Holdings into a low-open, high-close session, up 5.62% to HK$10.71 on HK$124.76 million turnover, with the HK$10.27 open marking the day's low and HK$10.72 touched at 15:04 in the afternoon session. The company repurchased 500,000 shares on 3 November and 200,000 on 4 November for about HK$4.72 million and HK$1.96 million, cushioning a stock that had printed a 52-week low of HK$9.28 on 2 November, while NMPA approval of subcutaneous batoclimab for generalized myasthenia gravis — China's first FcRn biologic — sits alongside a consensus target price raised 20% to HK$24.48 and China Merchants Securities initiating coverage at HK$28. Q2 revenue rose 20.79% year on year to HK$480.3 million with a 52.97% net margin, yet the shares remain below the MA60 of HK$13.07, down 11.34% year to date and 37.26% below the 25 August high of HK$17.07, while net profit still fell 9.62%.
- Nov, 4
HBM Holdings shook off early weakness and firmed through the afternoon, closing at HK$10.11 versus a HK$9.40 previous close, a gain of roughly 7.6%, after repurchasing another 500,000 shares for about HK$4.72 million on November 3, extending a buyback run begun in late October. The more substantive driver was NMPA approval of subcutaneous batoclimab (HBM9161) for generalised myasthenia gravis, the first FcRn biologic cleared in China, together with China Merchants Securities International initiating coverage with a HK$28 target and the consensus target rising to HK$24.48 from HK$20.40. Q2 revenue of HK$480.3 million grew 20.8% year on year at a 52.97% net margin, though net profit fell 9.6% and EPS of HK$0.3041 slipped 13.9%, leaving the stock on 12.86x PE. Even after today's move it is down 18.9% year to date, 42.6% below the August 25 high of HK$17.07 and still under its MA20 (HK$10.41) and MA60 (HK$13.15), having set a 52-week low of HK$9.28 on November 2.
- Nov, 3
Approval and buybacks failed to hold the stock: 2142.HK reversed early gains, printing an intraday high of HK$9.69 at 10:49 before sliding to HK$9.30 by 14:54 and closing at HK$9.36, down 4.3% on HK$57.1 million turnover. The operating picture contrasts with the tape: Q2 2026 revenue rose 20.8% year on year to HK$480.3 million with a 53.0% net margin, yet net profit fell 9.6% to HK$254.4 million and EPS slipped 13.9% to HK$0.3041. The shares sit near the 52-week floor, 45.2% below the 25 August high of HK$17.07 and down 22.5% year to date, trading under the MA20 of HK$10.58. China Merchants Securities International initiated coverage with a HK$28 target, the consensus target was raised 20% to HK$24.48, and the company repurchased 200,000 shares for HK$1.9514 million on 2 November, though the stock still marked a fresh 52-week low.
- Oct, 27
GIC's disposal of 753,000 shares at about HK$10.37, alongside broad weakness in Hong Kong biotech, left HBM Holdings down 4.03% at HK$9.77 on 27 October after a spike-and-fade session: the stock printed a HK$10.22 intraday high before sliding to HK$9.65 at 14:16 BJ, on roughly HK$65 million of turnover. Neither the NMPA approval of subcutaneous batoclimab for generalized myasthenia gravis nor buybacks of about 2.7 million shares between 13 and 20 October arrested the selling. Q2 2026 revenue of HK$480.3 million rose 20.79% year on year, yet net profit of HK$254.4 million fell 9.62%. At HK$9.77 the shares sit below the MA20 of HK$11.53 and MA60 of HK$13.48, down 19.12% year to date, 42.77% below the 52-week high of HK$17.07 and just 3.28% above the HK$9.46 low. China Merchants Securities International initiated coverage with a HK$28 target, though whether the earnings base translates into share performance remains to be seen.
News
Weekly Review · Weekly Recap | HBM HOLDINGS-B -1.86%, most brokers rate it buy
Weekly Review · Weekly Recap | HBM HOLDINGS-B +6.13%, myasthenia gravis drug approved
Simplywall · Harbour BioMed Stock In Focus After China Approval For Myasthenia Gravis Drug
prnewswire · Harbour BioMed Appoints Ms. Vivian Feng as Head of External Collaboration
Market Movers · HBM Holdings climbs 6%
Market Movers · HBM Holdings hits 52-week low
